# Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma

> **NCT01127451** · PHASE2 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 75 (actual)

## Conditions studied

- Stage IIIC Melanoma
- Stage IV Melanoma

## Interventions

- **DRUG:** Denileukin diftitox

## Key facts

- **NCT ID:** NCT01127451
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06-22
- **Primary completion:** 2015-04-07
- **Final completion:** 2015-04-07
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2022-04-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01127451

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01127451, "Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01127451. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*